← Oncology Approval Tracker

FDA DECISION ·

Zepzelca

lurbinectedin · Pharma Mar

Accelerated approvalNew therapySmall cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Sep 30, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy.

LAMPGEN ANALYSIS

Why it matters

Added an option after platinum failure in a disease with few approved later-line therapies at the time.

What research teams should watch

Record the platinum-free interval and ensure blood counts are available before each cycle.

PRIMARY RECORDS

Sources